Immunitybio Inc (IBRX NASDAQ) stock market data APIs
$2.6239
0.1(3.8%)
as of June 30, 2025
Try our APIs with
free plan!
Immunitybio Inc Financial Data Overview
Price chart is built with
Anychart
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Prev. Close
2.6239
Open
2.7235
High
2.7842
Low
2.6371
52 wk Range
1.83-7.48
Market Cap
2 383 M
Shares Outstanding
883 M
Revenue
31 222 K
EPS
-0.15
Beta
-0.065
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunitybio Inc data using free add-ons & libraries
Get Immunitybio Inc Fundamental Data
Immunitybio Inc Fundamental data includes:
- Net Revenue: 31 222 K
- EBITDA: -296 588 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.16
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunitybio Inc News
New
ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it attained Expanded Access authoriza...
Exploring High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has risen 1.2% and is up 11% over the last 12 months, with earnings forecast to grow by 14% annually. In this context of steady growth, identifying high-...
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other Wednesday's best-perfo...
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield
ImmunityBio (IBRX) announced that the U.S. Food and Drug Administration, FDA, has granted Expanded Access authorization for the use of its Cancer BioShield platform, anchored by ANKTIVA, to treat lymp...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
